SGS Life Science Services to Invest in its Mumbai, India, Facility

SGS Life Science Services is to invest in its Mumbai, India, facility — a move that will see the current 1393 m2 laboratory more than double in size, to 3994 m2. The expansion is being driven by increasing demand for full time Equivalent (FTE) activities for key pharmaceutical customers, as well as more stability projects from both local operations of multinational companies and overseas organisations.

The expanded laboratory will act as a dedicated cGMP pharmaceutical testing site and is due for completion and validation in Q2 2015.

The Mumbai facility, which is focused on stability studies and dedicated FTE models, will feature three new 100-m3 capacity stability chambers, HPLCs, dissolutions, gas chromatographs and additional general laboratory instruments. Capacity at the site will grow from 423 m3 to 723 m3, while the current 88 strong workforce will ultimately be augmented by an additional 39 members of staff.

“The expansion will bring additional facilities, expertise and personnel to serve our customers’ requirements in Asia,” commented Paul House, Managing Director of SGS India Ltd. “Upon completion, the Mumbai laboratory will be the largest stability testing facility in our Life Science Services network.”